BiotechTube
Home/Atonco/Adrien REYMOND
AR

Adrien REYMOND

Business Development Director

Atonco

Therapeutic Areas

Oncology

Atonco Pipeline

DrugIndicationPhase
Astatine-211-labeled anti-CAIX antibody (girentuximab)Non-Muscle Invasive Bladder Cancer (NMIBC), refractory to BCG/chemotherapyPre-clinical

Leadership Team at Atonco

SF
Sylvain FANIER
CEO
JC
Jean-François CHATAL
Chief Medical Officer
JB
Jacques BARBET
Chief Scientific Officer
A(
Alexandra (GITEAU) PAILLARD
COO
CM
Clément MAYEUR
Chief Financial Officer
DB
Denis BILODEAU
Clinical Research Developer
View full Atonco profile